Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
13 March 2023 |
Main ID: |
NCT02283853 |
Date of registration:
|
03/11/2014 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
CONNECT |
Scientific title:
|
Open-Label, Randomized, Multicenter, Multiple-Dose,Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension |
Date of first enrolment:
|
August 28, 2014 |
Target sample size:
|
156 |
Recruitment status: |
Active, not recruiting |
URL:
|
https://clinicaltrials.gov/show/NCT02283853 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
Phase:
|
Phase 3
|
|
Countries of recruitment
|
Argentina
|
Belgium
|
Bulgaria
|
Canada
|
Czech Republic
|
Czechia
|
Denmark
|
France
|
Germany
|
Hungary
|
Israel
|
Italy
|
Kuwait
|
Poland
|
Romania
|
Serbia
|
Spain
|
Sweden
|
Turkey
|
United Kingdom
|
United States
| | | |
Contacts
|
Name:
|
Medical Director |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Biogen |
| | |
Key inclusion & exclusion criteria
|
Key Inclusion Criteria:
- Must have a body weight of =30 kg.
- Must have a diagnosis of RRMS (consensus definition for pediatric RRMS [Krupp 2007]).
- Must be ambulatory with a baseline EDSS score between 0 and 5.5, inclusive.
- Must have experienced at least 1 of the following 3 conditions: a) at least 1 relapse
within the last 12 months prior to Day 1 with a prior brain MRI demonstrating lesions
consistent with MS; b) at least 2 relapses within the last 24 months prior to Day 1,
with a prior brain MRI demonstrating lesions consistent with MS; c) evidence of
Gd-enhancing lesions of the brain on an MRI performed within the 6 weeks prior to Day
1.
- Must be neurologically stable, with no evidence of relapse within 50 days prior to Day
1 and no evidence of corticosteroid treatment within 30 days prior to Day 1.
- Subjects of childbearing potential who are sexually active must be willing to practice
effective contraception during the study and be willing and able to continue
contraception for at least 30 days after their final dose of study treatment.
Key Exclusion Criteria:
- Primary progressive, secondary progressive, or progressive relapsing MS (as defined by
[Lublin and Reingold 1996]). These conditions require the presence of continuous
clinical disease worsening over a period of at least 3 months. Subjects with these
conditions may also have superimposed relapses but are distinguished from
relapsing-remitting subjects by the lack of clinically stable periods or clinical
improvement.
- Disorders mimicking MS, such as other demyelinating disorders (e.g., acute
disseminated encephalomyelitis), systemic autoimmune disorders (e.g., Sjögren disease,
lupus erythematosus), metabolic disorders (e.g., dystrophies), and infectious
disorders.
- History of premalignant or malignant disease. Subjects with basal cell carcinoma that
has been completely excised prior to screening will remain eligible.
- History of severe allergic or anaphylactic reactions, or known drug hypersensitivity
to DMF, fumaric acid esters, or interferon beta-1a (IFN Beta-1a).
- History of abnormal laboratory results indicative of any significant endocrinologic,
hematologic, hepatic, immunologic, metabolic, urologic, renal, and/or any other major
disease that would preclude participation in a clinical study.
- History of clinically significant cardiovascular, pulmonary, GI, dermatologic, growth,
developmental, psychiatric (including depression), neurologic (other than MS), and/or
other major disease that would preclude participation in a clinical study.
-.History of human immunodeficiency virus.
- An MS relapse that has occurred within 50 days prior to Day 1 AND/OR the subject has
not stabilized from a previous relapse prior to Day 1.
- Other unspecified reasons that, in the opinion of the Investigator or Biogen Idec,
make the subject unsuitable for enrollment.
- For the PD/PK subset of subjects: subjects unable to swallow the BG00012 capsule
whole.
Key Treatment history
- Any previous treatment with Fumaderm (fumaric acid esters) or BG00012.
- Prior treatment with any of the following: total lymphoid irradiation, cladribine,
T-cell or T-cell receptor vaccination, any therapeutic monoclonal antibody, with the
exception of rituximab or natalizumab.
- Prior treatment with any of the following medications within the 12 months prior to
Day 1: mitoxantrone, cyclophosphamide, rituximab.
- Prior treatment with any of the following medications or procedures within 6 months
prior to Day 1: fingolimod; teriflunomide; natalizumab; cyclosporine; azathioprine;
methotrexate; mycophenolate mofetil; laquinimod; intravenous (IV) immunoglobulin;
plasmapheresis or cytapheresis
- Treatment with any of the following medications within 30 days prior to Day 1:
steroids (IV or oral corticosteroid treatment, including agents that may not act
through the corticosteroid pathway [e.g.low dose naltrexone]), 4-aminopyridine or
related products (except subjects on a stable dose of controlled-release fampridine
for 3 months)
NOTE: Other protocol-defined inclusion/exclusion criteria may apply
Age minimum:
10 Years
Age maximum:
17 Years
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
Relapsing-Remitting Multiple Sclerosis
|
Intervention(s)
|
Drug: dimethyl fumarate
|
Drug: Interferon ß-1a
|
Primary Outcome(s)
|
Number of Participants Who Discontinue Study Treatment due to an AE
[Time Frame: Up to 7 years]
|
Proportion of Participants Free of New/Newly Enlarging T2 Hyperintense Lesions on Brain MRI Scans
[Time Frame: At week 96]
|
Number of Participants That Experience Adverse Events (AEs) or Serious Adverse Events (SAEs)
[Time Frame: Up to 7 years]
|
Secondary Outcome(s)
|
Number of Participants with Incidences of Clinically Relevant Vital Signs Abnormalities
[Time Frame: Up to 7 years]
|
Change from Baseline to Week 96 in the Expanded Disability Status Scale (EDSS) Score
[Time Frame: Up to Week 96]
|
Change from Baseline in Brief Visuospatial Memory Test - Revised (BVMT-R) Score
[Time Frame: Up to 7 years]
|
Change from Baseline in Weight
[Time Frame: Up to 7 years]
|
Annualized Relapse Rate
[Time Frame: At Weeks 48 and 96]
|
Change from Baseline in Bone Age
[Time Frame: Up to 7 years]
|
Proportion of Participants Free of New/Newly Enlarging T2 Hyperintense Lesions on Brain MRI Scans
[Time Frame: At Week 24 and Week 48]
|
Change from Baseline in EDSS Score
[Time Frame: Up to 7 years]
|
Change from Baseline in School Progression Query
[Time Frame: Up to 7 years]
|
Fatigue as measured by the Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue Scale Scores
[Time Frame: Up to Week 96]
|
Number of Participants with Incidences of Clinically Relevant Laboratory Assessment Abnormalities
[Time Frame: Up to 7 years]
|
Number of Participants That Experience Adverse Events (AEs) and Serious Adverse Events (SAEs)
[Time Frame: Up to Week 96]
|
Quality of Life as measured by the PedsQL
[Time Frame: Up to Week 96]
|
Annualized Relapse Rate
[Time Frame: Up to 7 years]
|
Change from Baseline in Height
[Time Frame: Up to 7 years]
|
Change from Baseline in Symbol Digit Modalities Test (SDMT) Score
[Time Frame: Up to 7 years]
|
Number of Participants with Incidences of Clinically Relevant ECG Abnormalities
[Time Frame: Up to 7 years]
|
Proportion of Participants Free of New MRI Activity as measured by Brain MRI Scans
[Time Frame: At Weeks 24, 48 and 96]
|
Tanner Stage
[Time Frame: Up to 7 years]
|
Time to First Relapse
[Time Frame: Up to Week 96]
|
Proportion of Participants Who Do Not Experience Relapse
[Time Frame: Up to Week 96]
|
The Number of New/Newly Enlarging T2 Hyperintense Lesions on Brain MRI Scans
[Time Frame: At Week 24 and Week 96]
|
Vital Signs, Electrocardiograms (ECGs) and Changes in Clinical Laboratory Data, including Monitoring of Liver Function, Renal Function, Hematologic, and Coagulation Parameters
[Time Frame: Up to Week 96]
|
Secondary ID(s)
|
109MS306
|
2013-002318-11
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|